Plus   Neg

Timken Guides FY20 Adj. EPS Below Estimates - Quick Facts

While reporting financial results for the fourth quarter on Wednesday, Timken Co. (TKR) initiated its earnings, adjusted earnings and revenue growth guidance for the full-year 2020.

For fiscal 2020, the company now projects earnings in a range of $4.00 to $4.40 per share and adjusted earnings in a range of $4.25 to $4.65 per share on revenue change between down 2 percent and up 2 percent , or roughly flat at the midpoint.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $4.66 per share on a revenue decline of 1.0 percent to $3.74 billion for the year. Analysts' estimates typically exclude special items.

"We expect profitability to improve meaningfully from fourth-quarter levels, and we remain focused on driving outgrowth, integrating recent acquisitions and advancing our operational excellence initiatives," said Richard Kyle, Timken president and chief executive officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker. Amazon.com, Inc. is in talks with mall operator Simon Property Group, Inc. to use the abandoned anchor departmental stores of JC Penny and Sears at their malls as fulfillment centers, reports said. This is expected to help the e-commerce giant in boosting their last mile delivery, which is the last leg of the delivery process. The U.S. Food and Drug Administration announced the approval of Trevena Inc.'s Olinvyk (oliceridine), a new opioid for intravenous use in hospitals or other controlled clinical settings. Olinvyk is an opioid agonist to manage moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
Follow RTT